

RevMedx, Inc.
25999 SW Canyon Creek Rd., Ste. C
Wilsonville, OR 97070
503.218.2172 www.revmedx.com
Document ID: RAW-0055-21

Label Issuance Date: 2017-08-15

XSTAT 30 Package Insert

NAME OF STUDY	GLP EVALUATION OF XSTAT DRESSING IN A SWINE FEMO		no VCTAT no Drodiento decesing uning the United Co.			
STUDY DESCRIPTION	GLP animal study to demonstrate the performance of the XSTAT Dressing compared to the XSTAT 30 Predicate dressing, using the United States					
NUMBER OF SUBJECTS	Army Institute of Surgical Research ("USAISR") standard femoral animal injury. Ten (10) animals were treated with the XSTAT dressing (Test Article)					
NOMBER OF SUBJECTS	Ten (10) animals were treated with the XSTAT dressing (1est Article) Ten (10) animals were treated with the XSTAT 30 predicate device (Control Article)					
INCLUSION / EXLUSION	Inclusion					
,	Animal breed: Landrace cross swine					
	 Weight at procedure: 55-65 kg 					
	 Age at procedure: 3-5 months (appropriate t 	o weight)				
			Hg) prior to femoral artery injury, and significant blood loss			
	(>300 mL) because of surgical complication or error before	e femoral artery injury.				
STUDY PROCEDURE	ALL WOUNDS PRIOR TO RANDOMIZATION					
			sues in the groin area directly over the left femoral artery			
	 and an approximately 3 cm section of femoral artery was exposed. The femoral artery was covered with a small piece of gauze and bathed with 2% lidocaine HCl solution to relax the vasospasm and dilate 					
	• The remoral artery was covered with a small piece of gauze and bathed with 2% ildocaine HCI solution to relax the vasospasm and dilate the artery to ≥ 5 mm outer diameter.					
	Non-traumatic vessel loops were placed prox	imally and distally on the femo	ral artery.			
	Using a 6.0 mm vascular punch, an arterioton	ny was created.				
	 The vessel loops were released, the injury sta 	art time was recorded and the v	ressel was allowed to bleed freely for 45 seconds before the			
	Test (XSTAT) or Control Article (XSTAT 30) wa					
	The vessel loops were allowed to remain in the	ne wound to facilitate hemorrh	age control during test material removal.			
	WOLLNDS BANDOMIZED TO VSTAT Drossing (Tost Article)					
	WOUNDS RANDOMIZED TO XSTAT Dressing (Test Article)	estructions for use (IELI) starting	g immediately following the 45-second free bleed.			
	= :: : :		bleeding has stopped, or until the 5-minute limit, whicheve			
	was sooner.	as many as necessary and the	biccaring has scopped, or artifacting of mindee infine, whileheve			
	A cloth bandage was wrapped around the lim	nb and firmly secured over the	packed wound.			
	Manual pressure was permitted if bleeding permitted in the permitted	ersisted following application o	of the dressing as per the IFU.			
	WOUNDS RANDOMIZED TO XSTAT 30 Predicate (Control Article)					
	 XSTAT 30 dressing was applied as per product instructions for use (IFU) starting immediately following the 45-second free bleed. 					
		oossible and as many as necess	ary until the bleeding stopped, until the 5-minute limit,			
	whichever was sooner.					
	 A cloth bandage was wrapped around the limb and firmly secured over the packed wound. Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU. 					
	Wandar pressure was permitted it breeding pr	ersisted following application c	if the dressing as per the iro.			
	POST-RANDOMIZATION CARE					
	Resuscitation began 5-25 minutes post-injury (i.e., free bleed start time) by infusing colloidal fluid (Hetastarch) at a target volume of					
	500mL into the jugular vein.					
			's solution (LRS). The total volume of LRS infused was			
			1 mL. The actual rate was then based on the volume of LRS			
		divided by the duration of infusion for each bag. If the MAP dropped to ~ 60 mmHg or less, LRS was infused into the jugular vein and				
	discontinued when the MAP of at least 65 mr • Following the 6-hour observation period, the	-	noved from the wound site and the animal euthanized.			
			with surgical forceps for both animals treated with test			
	articles and control articles.	would site mandally as well as	with surgical forceps for both animals treated with test			
	Following sponge removal and euthanasia, the sponge removal and euthanasia.	ne wound site was imaged usin	g a portable fluoroscopy unit.			
RESULTS	ENDPOINTS	XSTAT (Test Article)	XSTAT 30 (Control Article)			
	1: Bleeding Time, mean: Duration of bleeding (visible	1.8 (5.7) minutes	1.6 (3.7) minutes			
	blood shed from the wound site) occurring at any time					
	immediately following test material application until was					
	at exsanguination or end of the 6-hour observation					
	at exsaliguillation of end of the o-flodi observation					
	period.					
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of	0.1 (0.2) mL/kg	1.0 (3.0) mL/kg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time	0.1 (0.2) mL/kg	1.0 (3.0) mL/kg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until	0.1 (0.2) mL/kg	1.0 (3.0) mL/kg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period.					
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev):	0.1 (0.2) mL/kg 66 (4) mmHg	1.0 (3.0) mL/kg 65 (3) mmHg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period.					
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to	66 (4) mmHg	65 (3) mmHg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period.					
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately	66 (4) mmHg	65 (3) mmHg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital	66 (4) mmHg	65 (3) mmHg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to	66 (4) mmHg	65 (3) mmHg			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for	66 (4) mmHg 5:45 (0:00) hours	65 (3) mmHg 5:46 (0:01) hours			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the	66 (4) mmHg 5:45 (0:00) hours	65 (3) mmHg 5:46 (0:01) hours			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP >20 mmHg and PCO 2 >15 mmHg.	66 (4) mmHg 5:45 (0:00) hours	65 (3) mmHg 5:46 (0:01) hours			
	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP >20 mmHg and PCO 2 >15 mmHg. The presence or absence of distal limb ischemia was not as	66 (4) mmHg 5:45 (0:00) hours	65 (3) mmHg 5:46 (0:01) hours			
Observations from	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP >20 mmHg and PCO 2 >15 mmHg. The presence or absence of distal limb ischemia was not as skin.	66 (4) mmHg 5:45 (0:00) hours 100% ssessed in this study. There was	65 (3) mmHg 5:46 (0:01) hours 100% s no postmortem evidence of blood tracking beneath the			
Dbservations from	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP >20 mmHg and PCO 2 >15 mmHg. The presence or absence of distal limb ischemia was not as skin. Pre-clinical studies of device performance of deployment a	66 (4) mmHg 5:45 (0:00) hours 100% ssessed in this study. There was and surgical removal of XSTAT s	65 (3) mmHg 5:46 (0:01) hours 100% s no postmortem evidence of blood tracking beneath the sponges demonstrated that not all minisponges expanded			
Observations from Animal Study	period. 2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period. 3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period. 4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period. 5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP >20 mmHg and PCO 2 >15 mmHg. The presence or absence of distal limb ischemia was not as skin.	66 (4) mmHg 5:45 (0:00) hours 100% ssessed in this study. There was and surgical removal of XSTAT sesome sponges may fall from the study.	65 (3) mmHg 5:46 (0:01) hours 100% s no postmortem evidence of blood tracking beneath the sponges demonstrated that not all minisponges expanded ne wound outside the body or may be retained in the			



NAME OF STUDY	EVALUATION OF XSTAT DRESSING IN A SWINE SUBCLAVIAN MODEL				
STUDY DESCRIPTION	GLP animal study to demonstrate the performance of the XSTAT Dressing compared to the XSTAT 30 Predicate dressing, using the United States				
	Army Institute of Surgical Research ("USAISR") standard subclavian animal injury.				
NUMBER OF SUBJECTS	Ten (10) animals treated with XSTAT dressing (Test Article) and Ten (10) animals treated with XSTAT 30 predicate device (Control Article)				
INCLUSION / EXCLUSION	 Inclusion Animal Breed: Landrace cross swine Weight at procedure: 41-62 kg Age at procedure: 3-5 months (appropriate to weight) Exclusion criteria included inappropriate vessel anatomy, persistently low MAP (< 55 mmHg) prior to femoral artery injury, and significant blood loss (>300 mL) because of surgical complication or error before femoral artery injury. 				
STUDY PROCEDURE	ALL WOUNDS PRIOR TO RANDOMIZATION	error before femoral artery injury.			
STORT THOUSE OF THE	 An incision was created (5.0 cm long) through the skin and subcutaneous tissues over the left superficial pectoralus directly over the left subclavian artery and an approximately 4.0 cm section of subclavian artery was exposed. The femoral artery was covered with a small piece of gauze and bathed with 2% lidocaine HCl solution to relax the vasospasm and dilate the artery to ≥ 5 mm outer diameter. The subclavian artery and vein were transected and allowed to bleed freely for 30 seconds. 				
	 WOUNDS RANDOMIZED TO XSTAT Dressing (Test Article) XSTAT dressing was applied as per product instructions for use (IFU) starting immediately following the 30-second free bleed. XSTAT was applied as quickly as possible and as many as necessary until the bleeding has stopped, or until the 5-minute limit, whichever was sooner. At the discretion of the surgeon, a cloth bandage was wrapped around the limb and firmly secured over the packed wound. Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU. 				
	 WOUNDS RANDOMIZED TO XSTAT 30 Predicate (Control Article) XSTAT 30 dressing was applied as per product instructions for use (IFU) starting immediately following the 30-second free bleed. XSTAT 30 dressing was applied as quickly as possible and as many as necessary until the bleeding stopped, until the 5-minute limit, whichever was sooner. At the discretion of the surgeon, a cloth bandage was wrapped around the limb and firmly secured over the packed wound. Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU. 				
	 POST-RANDOMIZATION CARE Resuscitation began 5-25 minutes post-injury (i.e., free bleed start time) by infusing colloidal fluid (Hetastarch) at a target volume of 500mL into the jugular vein. Resuscitation was continued, if necessary, with pre-warmed lactated Ringer's solution (LRS). The total volume of LRS infused was based on pre-and post-use weights of the LRS infusion bags, assuming 1 g - 1 mL. The actual rate was then based on the volume of LRS divided by the duration of infusion for each bag. If the MAP dropped to ~ 60 mmHg or less, LRS was infused into the jugular vein and discontinued when the MAP of at least 65 mmHg was reached. Following the 1-hour observation period, the Test or Control Article was removed from the wound site and the animal euthanized. XSTAT minisponges were removed from the wound site manually as well as with surgical forceps for both animals treated with test articles and control articles. 				
DECLU TO	Following sponge removal and euthanas				
RESULTS	ENDPOINTS 1: Bleeding Time, mean: Duration of bleeding (visible blood shed from the wound site) occurring at any time immediately following test material application until was at exsanguination or end of the 6-hour observation period.	XSTAT (Test Article) 0.7 (2.2) minutes	XSTAT 30 (Control Article) 0.9 (2.9) minutes		
	Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period.	0.01 (0.03) mL/kg	0.2 (0.6) mL/kg		
	3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period.	65 (5) mmHg	68 (4) mmHg		
	4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP >20mmHg and PCO 2 >15 mmHg to exsanguination or end of the 6-hour observation period.	1:00 (0:00) hours	1:01 (0:03) hours		
	5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP >20 mmHg and PCO 2 >15 mmHg.	100%	100%		
	The presence or absence of distal limb ischemia was r skin.	not assessed in this study. There was	no postmortem evidence of blood tracking beneath the		



NAME OF STUDY	USER EVALUATION OF XSTAT 30	USER EVALUATION OF XSTAT 30 APPLICATION			
STUDY DESCRIPTION	A user evaluation (human factors) was completed to determine the ability of medics and civilian EMS and medical professionals to understand and execute instructions for using XSTAT 30 and applying XSTAT 30 on a simulated casualty.				
NUMBER OF SUBJECTS	11				
INCLUSION/EXCLUSION	Military or civilian EMS/Medical P	Military or civilian EMS/Medical Professionals with no prior knowledge or experience with XSTAT dressing prior to the study.			
STUDY PROCEDURE:	 A medical mannequin torso served as a wound model. The wound track – located in the upper thigh region approximately 5 cm distal to the iliac artery – had a diameter of 11 mm. Participants were evaluated on the ability to open the package, apply the applicator into the wound and deploy three (3) XSTAT 30 devices. In addition, participants were evaluated on the time needed to ready the device for use and deploy the device. Participants provided their evaluation on the use of the device, the packaging and Instructions for Use of the device, and the Training Video for the device. 				
RESULTS	PARTICIPANT	TIME	USER COMMENTS	ACTIONS TAKEN	
	1	36			
	2	41	Add detail on resistance when using device; improve outer packaging	Statement regarding resistance included in IFU and training video; final package labeled with easy open tear notches.	
	3	39	Show areas where device is not indicated	Final training video comprises images highlighting areas that are contraindicated.	
	4	34			
	5	30	Include real and animation in video if possible; improve outer packaging	Final training video comprises mostly animation; final package labeled with easy open tear notches	
	6	33			
	7	38	Improve outer packaging	Final package labeled with easy open tear notches	
	8	53			
	9	46	IFU and packaging should hold up to rain and wind conditions.	Final IFU printed on water resistant material and tested for water exposure and legibility.	
	10	39	Ensure proper pronunciation in video; improve outer packaging; make plunger brighter	Pronunciation of key medical terms confirmed; final package labeled with easy open tear notches; final plunger is white.	
	11	53	Improve outer packaging	Final package labeled with easy open tear notches	

NAME OF STUDY/CITED	USER EVALUATION OF XSTAT DRESSING REMOVAL				
PUBLICATION	SER EVILORITOR AS AN ORDESTING RELIGIONE				
STUDY DESCRIPTION	A user evaluation was completed to assess the ability of surgeons to understand and execute instructions for removing XSTAT sponges from human				
	cadaver wounds.				
NUMBER OF SUBJECTS	4 surgeons; 1 cadaver; 2 wounds; 2 tests/wound				
INCLUSION / EXCLUSION	Inclusion: civilian or military surgeon with no prior experience with XSTAT prior to the study				
STUDY PROCEDURE	Junctional wounds were made in each shoulder the cadaver				
	Saline solution was circulated through cadaver's vasculature to simulate blood flow.				
	Following application of 2 XSTAT devices into the shoulder wounds, each surgeon was handed draft instructions for use and instructed to treat				
	the wound.				
RESULTS	ENDPOINT	RESULT			
	 Labeling clear on use of XSTAT device (Yes / No) 	45			
	Completed all steps in IFU without assistance (Yes /	31			
	No)				
	IFU conveys necessity of removal of sponges, median*	47			
	IFU conveys steps to assure removal, median*	70			
	Effective order of removal steps, median*	43			
	6. Ease of removal of sponges, median*	71			
	*Scale: 1 = Poor, 2 = Fair, 3 = Acceptable, 4 = Good, 5 = Very Good				
USER	COMMENT	ACTION TAKEN			
COMMENTS/ACTIONS	Add reminder that all sponges must be removed before wound	Package label and casualty card contain explicit instructions for surgical			
TAKEN	closure.	sponge removal.			
	Note approximate number of sponges per applicator on the	Package updated to include number of sponges per applicator.			
	package.				

XSTAT 30 TRAINING INFORMATION

XSTAT 30 is a hemostatic dressing for the control of severe, life-threatening bleeding from junctional wounds in the groin or axilla not amenable to tourniquet application in adults and adolescents.

XSTAT 30 is a hemostatic dressing for the control of severe, life-threatening bleeding from narrow entrance extremity wounds in the arms or legs in adults and adolescents.

XSTAT 30 is a temporary dressing for use up to four (4) hours until surgical care is acquired. XSTAT should only be used for patients at high risk for immediate life-threatening bleeding from, hemodynamically significant (Advanced Trauma Life Support class 3 or 4 hemorrhagic shock), non-compressible junctional wounds or narrow entrance extremity wounds, and when definitive care at an emergency care facility cannot be achieved within minutes.

XSTAT 30 is NOT indicated for use in: the thorax, the pleural cavity, the mediastinum, the abdomen, the retroperitoneal space, the sacral space; tissues above the inguinal ligament, or tissues above the clavicle.

XSTAT 30 contains rapidly expanding cellulose sponges and individually marked with an X-shaped radiopaque marker. XSTAT 30 works by applying the small sponges into a wound cavity using a lightweight applicator. In the wound, the XSTAT 30 sponges expand and create a barrier to blood flow, present a large surface area for clotting, and provide gentle pressure.

The XSTAT 30 applicator is comprised of three primary parts:

- The main applicator which holds approximately 92 XSTAT minisponges
- A telescoping handle
- A bifurcated silicone tip that allows the XSTAT to exit



XSTAT 30 TRAINING INFORMATION CONTINUED

XSTAT is a hemostatic dressing for the control of bleeding from junctional wounds in the groin or axilla or narrow entrance extremity wounds in the arms or legs. In narrow, deep wounds, XSTAT works by expansion of cellulose sponges against the walls of the cavity to apply pressure inside the wound.

Prior to using XSTAT, fully examine the injured patient and assess for signs of bleeding. Arterial bleeding is caused by the laceration of an artery and is the most difficult type of blood loss to control. Arterial hemorrhage is characterized by spurting blood that is bright red in color. Even a small, deep, arterial puncture wound can produce significant blood loss.

If the wound is not amenable to tourniquet use and is located on the groin or axilla, it is a junctional wound. In the testing of the XSTAT dressing, hemorrhage from the groin was created in a swine using a 6.0mm vascular punch on the femoral artery. The injury bled for 45 seconds prior to device application. The XSTAT dressing would be appropriate for use under comparable conditions.

If the hemorrhage cannot be identified or the anatomical location is not a junctional or extremity wound, XSTAT is not the preferred dressing to achieve hemorrhage control and alternative treatments should be used such as other hemostatic dressings or tourniquets.

XSTAT is NOT indicated for use in: the thorax, the abdomen, the retroperitoneal space, the sacral space; tissues above the inguinal ligament, or tissues above the clavicle.

XSTAT has not been tested for use in extremity wounds that are amenable to tourniquet application. XSTAT use in conjunction with tourniquet application has not been assessed for use in extremity wounds that are amenable to tourniquet application.

- Read Indications for use and warnings and cautions on front label and back label.
- · Open package and remove applicator.
- Pull the black handle out and away from barrel until it stops and locks.
- Place the tip of the applicator into the wound track as close to the bleeding source as possible.
- Firmly depress black handle to deploy dressing into the wound. Material should flow freely into the wound.
- DO NOT attempt to forcefully eject the material from the applicator. If resistance is met pull back slightly on the applicator body to create additional packing space, then continue to depress handle.
- Use additional applicators as necessary to completely pack the wound with dressing.

NOTE: XSTAT hemostatic devices are available in two sizes: XSTAT 30 and XSTAT 12. The XSTAT 12 applicator has a 12 mm outer diameter and the XSTAT 30 has a 30 mm outer diameter. If the entrance of the wound is too narrow to access with an XSTAT 30, then XSTAT 12 is the preferred device to achieve hemorrhage control.

- Cover the wound with an occlusive or pressure dressing. If available, use an elastic bandage.
- If bleeding persists, apply manual pressure until bleeding is controlled.
- DO NOT attempt to remove dressing from wound. Sponges must be removed intraoperatively by surgeon with the capability and equipment for achieving proximal and distal vascular control.
- Remove the included casualty card from the outer pouch. Assess patient for peripheral circulation and document presence of distal pulse on included casualty card.
- WARNING: Vascular compression greater than four hours is not recommended due to concerns related to limb ischemia.







Triangular segments of the applicator tip may break away from applicator during treatment. If this occurs, do not attempt to retrieve if from the wound.

Record number of separated applicator tips on casualty card.

- After completion of treatment, fill out the casualty card completely. A line has been added above the notes depicting the amount of XSTAT applicators used to treat the wound. Circle the appropriate number. If any applicator tips were released from the applicator, record that in the notes section.
- Document clinical assessments, treatments rendered, and changes in the casualty's status on the included casualty card. The casualty card also contains instructions for removing XSTAT sponges from the wound. Forward this information with the casualty to the next level of care.
- In addition to directly communicating patient information to the next provider in the chain of care, attach the casualty card to the patient in a visible location. A safety pin and rubber band are included with the casualty card to facilitate attachment.
- Preferably, attach the casualty card near the wound. For example, using the safety pin, the card may be attached to the occlusive or pressure dressing used to cover the wound, or if possible to a nearby portion of clothing. If attachment near the wound is not possible, alternative locations may include the wrist, ankle, clothing of the upper/lower torso, patient record holders on the litter or hypothermia prevention kit. It is important that regardless of the means utilized to attach the card the information on the card reaches the surgeon with the patient.

XSTAT DRESSING REMOVAL:

- Survey the wound site and assess potential vascular bleeding sites and develop plan to achieve surgical control of injured vessel(s).
- Remove sponges from the wound site manually and/or with surgical forceps to the site(s) of bleeding.
- Thoroughly explore wound and removal all sponges.
- Prior to wound closure, obtain plane X-ray optimally in more than one projection. The presence of retained sponge may be easily missed on radiographic images.

 Thoroughly examine X-ray for radiopaque x-pattern of sponges or any triangular segments of the applicator tip that may be inadvertently retained in the wound cavity.
- If sponges or applicator tip segments are identified via X-ray, carefully re-examine wound cavity and remove sponges. Perform and review second X-ray to confirm complete sponge removal.

WARNING:

- 1. Relying upon sponge count alone post removal is not an accurate means of determining complete minisponge removal from the wound.
- 2. Careful surgical exploration of the wound site is required to ensure complete sponge removal from the wound.
- 3. Confirmation of complete removal from the wound by XRay is required to search for possible retained minisponges.
- 4. Review of XRays to identify potential retained XSTAT minisponges should be performed by physicians trained to review surgical XRays.
- 5. While the minisponges are designed with an X-pattern radio-opaque marker, it may be confused with other radio-opaque material in the wound, such as bone chips and wound clips.